Eli Lilly stock weekly forecast: Support at $1,284 comes into focus after recent gains

Traders Union
All News
Stocks
Eli Lilly slips 0.58% this week

Highlights

Shares of Eli Lilly have edged lower over the past week, holding well above major daily averages in a bullish structure.
Technical indicators show momentum is overbought, yet underlying trend strength remains intact with MACD indicating ongoing upside momentum.
For the upcoming week, shares are projected to trade in a $1,340 to $1,478 range, with support at $1,284 and resistance at $1,436.

Revenue guidance raised as obesity and diabetes drugs drive weekly sentiment

Eli Lilly reported strong third-quarter 2026 results with revenue of $24.4 billion and net income of $6.5 billion, driven by robust sales of its obesity drug Zepbound and diabetes treatment Mounjaro, according to Yahoo Finance. The company raised its full-year 2026 revenue guidance to between $91 billion and $92 billion after this outperformance. Product volumes climbed 53%, though realized prices declined 15% as noted by PR Newswire. ETF allocations to LLY shares also increased, led by fresh purchases from XLV.

Overbought signals emerge as trend strength persists through the week

On the daily chart, momentum shows signs of potential overheating as RSI, CCI, and Stochastic RSI are all in overbought territory, with RSI at 75.33. Despite the overbought signals, trend strength remains intact and the MACD continues to indicate upside momentum. The nearest support lies at $1,284, anchored by the Ichimoku Kijun, while resistance sits at $1,436 near the weekly high. Recent volatility stands at 11.97%, and the underlying structure suggests a sustained move lower could develop if initial support breaks, but trend continuation has not been invalidated.

Breakout scenarios build as price range narrows in the coming week

For the coming trading week, Eli Lilly shares are expected to trade within a range of $1,340 to $1,478. There is a 78% probability of an increase and a 22% probability of a decrease. The base case favors price holding between support at $1,284 and resistance at $1,436. A sustained breakout above $1,436 would open the door for further gains toward the high end of the expected range. Conversely, a decisive move below $1,284 could trigger a deeper downside correction.

Jainam Mehta, market strategist, notes that shares of Eli Lilly are consolidating near $1,409 with momentum running hot following a strong weekly recovery. He sees the fundamental strength underscored by robust Q3 2026 results, surging product volumes, and increased ETF allocations to LLY shares, but cautions that daily technical readings such as the RSI at 75.33 and other overbought signals suggest short-term risks of a pullback are increasing. The base case is for shares to remain capped between $1,284 support and $1,436 resistance, with volatility leaving room for tactical trades should either level break decisively in the coming days. "Sustained strength above $1,436 could fuel another leg higher, but I am watching initial support at $1,284 closely — a break there would likely shift the narrative to short-term caution."

Earlier, analysts noted that Eli Lilly's strong earnings and rising revenue expectations were fueling a sustained bullish bias in the stock. With momentum now stretched and technical signals indicating overbought conditions, the key focus for traders shifts to whether support near $1,284 can withstand potential downside pressure in the near term.

Source of Data: LLY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.